Health X Platform Q2 FY27 consolidated revenue Rs 489.10 cr, loss narrows
Health X Platform Limited’s Q2 FY27 consolidated revenue from operations rose to Rs 489.10 cr from Rs 307.90 cr, with loss after tax improving to Rs (12.70) cr from Rs (15.40) cr.
Key takeaways
- Revenue from Operations rose to Rs 489.10 cr in Q2 FY27 from Rs 307.90 cr in Q2 FY26.
- Gross Margin increased to Rs 40.70 cr in Q2 FY27 from Rs 22.90 cr a year earlier.
- EBITDA was Rs (17.20) cr in Q2 FY27 versus Rs (16.00) cr in Q2 FY26, with EBITDA % at (3.5%) vs (5.2%).
- Profit/(Loss) for the period/Year improved to Rs (12.70) cr from Rs (15.40) cr, with PAT % at (2.6%) vs (5.0%).
- Finance Costs were Rs 0.90 cr in Q2 FY27 compared with Rs 0.00 cr in Q2 FY26.
Q2 FY27 · consolidated
| Metric | Sep 2026 | Sep 2025 | Change |
|---|---|---|---|
| Revenue | Rs 489.10 cr | Rs 307.90 cr | +58.8% |
| PAT | Rs (12.70) cr | Rs (15.40) cr | +17.5% |
| Margin | (2.6%) | (5.0%) | +240 bps |
As reported in the filing. Figures are transcribed, not computed.
• Revenue from Operations (Q2 FY27 vs Q2 FY26): Rs 489.10 cr vs Rs 307.90 cr
• Cost of Materials Consumed: Rs 448.40 cr vs Rs 285.00 cr
• Gross Margin: Rs 40.70 cr vs Rs 22.90 cr
• GM %: 8.3% vs 7.5%
• Employee Benefits Expense: Rs 31.00 cr vs Rs 19.90 cr
• Other Expenses: Rs 26.90 cr vs Rs 19.10 cr
• EBITDA: Rs (17.20) cr vs Rs (16.00) cr
• EBITDA %: (3.5%) vs (5.2%)
• Other Income: Rs 5.40 cr vs Rs (1.10) cr
• Depreciation and Amortisation Expense: Rs 2.50 cr vs Rs 1.30 cr
• EBIT: Rs (14.40) cr vs Rs (18.40) cr
• Finance Costs: Rs 0.90 cr vs Rs 0.00 cr
• Exceptional Items: Rs 0.00 cr vs Rs (0.20) cr
• PBT: Rs (15.20) cr vs Rs (18.60) cr
• Total Tax Expense/ (Income): Rs (2.50) cr vs Rs (3.20) cr
• Profit/(Loss) for the period/Year: Rs (12.70) cr vs Rs (15.40) cr
• PAT %: (2.6%) vs (5.0%)
• Share of profit/(loss) from Associate: Rs 0.00 cr vs Rs 0.00 cr
• Profit/(Loss) for the period/Year after share of associate: Rs (12.70) cr vs Rs (15.40) cr
According to the Q2 FY27 consolidated profit and loss statement in the investor presentation, Health X Platform Limited reported revenue from operations of Rs 489.10 cr for Q2 FY27, compared with Rs 307.90 cr in Q2 FY26. Cost of materials consumed increased to Rs 448.40 cr from Rs 285.00 cr. As a result, gross margin rose to Rs 40.70 cr in Q2 FY27 from Rs 22.90 cr a year earlier, with the reported GM % moving to 8.3% from 7.5%.
Employee benefits expense for the quarter was Rs 31.00 cr, up from Rs 19.90 cr in Q2 FY26, while other expenses increased to Rs 26.90 cr from Rs 19.10 cr. EBITDA was reported at Rs (17.20) cr in Q2 FY27 versus Rs (16.00) cr in the corresponding quarter of the previous year, with EBITDA % shown at (3.5%) compared with (5.2%). Other income stood at Rs 5.40 cr in Q2 FY27 against Rs (1.10) cr in Q2 FY26. Depreciation and amortisation expense rose to Rs 2.50 cr from Rs 1.30 cr.
EBIT improved to Rs (14.40) cr in Q2 FY27 from Rs (18.40) cr in Q2 FY26. Finance costs were Rs 0.90 cr versus Rs 0.00 cr a year earlier. Exceptional items were reported at Rs 0.00 cr in Q2 FY27 compared with Rs (0.20) cr in Q2 FY26. Profit before tax (PBT) came in at Rs (15.20) cr, compared with Rs (18.60) cr in the same quarter last year. Total tax expense/(income) was Rs (2.50) cr versus Rs (3.20) cr.
Profit/(loss) for the period/year attributable on the consolidated basis was Rs (12.70) cr in Q2 FY27, compared with Rs (15.40) cr in Q2 FY26, with PAT % reported at (2.6%) versus (5.0%). Share of profit/(loss) from associate was Rs 0.00 cr in both periods, leaving the consolidated profit/(loss) for the period/year unchanged at Rs (12.70) cr versus Rs (15.40) cr.
Track Health X Platform Ltd
Cruxal reads every Health X Platform Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Get every filing that moves a stock
One email before the open, with the day's filings that actually shifted a price — the number, the source document and what the market did with it. Free, and you can unsubscribe from any issue.
Cruxal publishes market coverage for information only. Nothing here is investment advice.